buy

GSK to buy RAPT Therapeutics in $2.2B deal

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies. GSK is paying $58 per share for the South San Francisco biotech, … [Read more…]

Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease. Lilly will acquire Verve for $10.50 per share, a premium of nearly 70% to the biotech’s share price at Monday’s close. The deal also includes an additional payment of $3 per share contingent on the first patient … [Read more…]